Estradiol/drospirenone

From Wikipedia, the free encyclopedia
Estradiol/drospirenone
Estradiol.svg
Estradiol
Drospirenone.svg
Drospirenone
Combination of
EstradiolEstrogen
DrospirenoneProgestogen; Progestin; Antimineralocorticoid; Antiandrogen
Clinical data
Trade namesAngeliq
Other namesE2/DRSP; BAY-864891
Routes of
administration
By mouth
Drug classEstrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
Legal status
Legal status
Identifiers
CAS Number

Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.[1][2][3] It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet.[1] The medication was approved in the United States in 2005.[1] It is marketed widely throughout the world.[4]

See also[edit]

References[edit]

  1. ^ a b c "ANGELIQ (drospirenone and estradiol) Prescribing Information" (PDF). Bayer HealthCare Pharmaceuticals Inc. U.S. Food and Drug Administration. February 2012.
  2. ^ "Estradiol/Drospirenone - Bayer HealthCare Pharmaceuticals". AdisInsight.
  3. ^ Rosano GM, Vitale C, Marazzi G, Volterrani M (February 2007). "Menopause and cardiovascular disease: the evidence". Climacteric. 10 (Suppl 1): 19–24. doi:10.1080/13697130601114917. PMID 17364594. S2CID 7305124.
  4. ^ "Drospirenone and Estradiol: Uses, Side Effects & Warnings".

External links[edit]